Literature DB >> 29953586

Quantitative positron emission tomography-guided magnetic resonance imaging postprocessing in magnetic resonance imaging-negative epilepsies.

Yicong Lin1,2, Yu-Hua Dean Fang3, Guiyun Wu4, Stephen E Jones5, Richard A Prayson6, Ahsan N V Moosa2, Margit Overmyer7, James Bena8, Mykol Larvie4,5, William Bingaman9, Jorge A Gonzalez-Martinez9, Imad M Najm2, Andreas V Alexopoulos2, Z Irene Wang2.   

Abstract

OBJECTIVE: Detection of focal cortical dysplasia (FCD) is of paramount importance in epilepsy presurgical evaluation. Our study aims at utilizing quantitative positron emission tomography (QPET) analysis to complement magnetic resonance imaging (MRI) postprocessing by a morphometric analysis program (MAP) to facilitate automated identification of subtle FCD.
METHODS: We retrospectively included a consecutive cohort of surgical patients who had a negative preoperative MRI by radiology report. MAP was performed on T1-weighted volumetric sequence and QPET was performed on PET/computed tomographic data, both with comparison to scanner-specific normal databases. Concordance between MAP and QPET was assessed at a lobar level, and the significance of concordant QPET-MAP+ abnormalities was confirmed by postresective seizure outcome and histopathology. QPET thresholds of standard deviations (SDs) of -1, -2, -3, and -4 were evaluated to identify the optimal threshold for QPET-MAP analysis.
RESULTS: A total of 104 patients were included. When QPET thresholds of SD = -1, -2, and -3 were used, complete resection of the QPET-MAP+ region was significantly associated with seizure-free outcome when compared with the partial resection group (P = 0.023, P < 0.001, P = 0.006) or the no resection group (P = 0.002, P < 0.001, P = 0.001). The SD threshold of -2 showed the best combination of positive rate (55%), sensitivity (0.68), specificity (0.88), positive predictive value (0.88), and negative predictive value (0.69). Surgical pathology of the resected QPET-MAP+ areas revealed mainly FCD type I. Multiple QPET-MAP+ regions were present in 12% of the patients at SD = -2. SIGNIFICANCE: Our study demonstrates a practical and effective approach to combine quantitative analyses of functional (QPET) and structural (MAP) imaging data to improve identification of subtle epileptic abnormalities. This approach can be readily adopted by epilepsy centers to improve postresective seizure outcomes for patients without apparent lesions on MRI. Wiley Periodicals, Inc.
© 2018 International League Against Epilepsy.

Entities:  

Keywords:  MRI postprocessing; MRI-negative epilepsy; focal cortical dysplasia; presurgical evaluation; quantitative positron emission tomography

Mesh:

Year:  2018        PMID: 29953586     DOI: 10.1111/epi.14474

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

Review 1.  Utility of MRI, PET, and ictal SPECT in presurgical evaluation of non-lesional pediatric epilepsy.

Authors:  Csaba Juhász; Flóra John
Journal:  Seizure       Date:  2019-05-11       Impact factor: 3.184

2.  Individual [18F]FDG PET and functional MRI based on simultaneous PET/MRI may predict seizure recurrence after temporal lobe epilepsy surgery.

Authors:  Jingjuan Wang; Kun Guo; Bixiao Cui; Yaqin Hou; Guoguang Zhao; Jie Lu
Journal:  Eur Radiol       Date:  2022-01-13       Impact factor: 5.315

3.  Morphometric analysis program and quantitative positron emission tomography in presurgical localization in MRI-negative epilepsies: a simultaneous PET/MRI study.

Authors:  Kun Guo; Jingjuan Wang; Zhenming Wang; Yihe Wang; Bixiao Cui; Guoguang Zhao; Jie Lu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-23       Impact factor: 10.057

4.  7T MRI with post-processing for the presurgical evaluation of pharmacoresistant focal epilepsy.

Authors:  Cong Chen; Juan-Juan Xie; Fang Ding; Ya-Si Jiang; Bo Jin; Shan Wang; Yao Ding; Hong Li; Biao Jiang; Jun-Ming Zhu; Mei-Ping Ding; Zhong Chen; Zhi-Ying Wu; Bao-Rong Zhang; Yi-Cheng Hsu; Hsin-Yi Lai; Shuang Wang
Journal:  Ther Adv Neurol Disord       Date:  2021-06-08       Impact factor: 6.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.